Nektar Therapeutics reiterated earnings guidance for the year 2024. The company still expect revenue for the full year to be between $75 million and $85 million, which includes $55 million to $65 million in noncash royalties and $20 million to $25 million in product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | -8.55% |
|
-6.14% | +89.38% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.38% | 197M | |
+55.19% | 815B | |
+45.42% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+10.18% | 302B | |
+18.18% | 247B | |
+2.25% | 229B | |
+13.17% | 219B | |
+10.86% | 171B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024